SDI Limited reports a flat sales performance for FY25 with regional growth offset by declines in key markets, while advancing its Montrose facility project with funding plans underway.
- Total sales marginally down 0.2% to $111 million
- European and Brazilian markets show solid growth
- Amalgam product sales decline by over 20%
- Gross profit margin improves to 63%
- Montrose project tender process progressing, funding via sale-leaseback and debt
Steady Sales Amid Mixed Regional Performance
SDI Limited, a key player in dental technology, has released a trading update for the fiscal year ending June 30, 2025, revealing a near-flat sales performance. Total sales reached $111 million, a slight dip of 0.2% compared to the previous year. This overall stability masks contrasting regional trends, with Europe and Brazil delivering encouraging growth of 7.2% and 9.9% respectively, while sales in the Middle East and Asia declined.
Notably, the company continues to face challenges with its Amalgam product line, which saw a significant 20.4% drop in sales, particularly in North America and Europe. This decline reflects ongoing shifts in dental material preferences and regulatory pressures in these markets.
Improved Margins and Controlled Expenses
Despite the sales headwinds, SDI managed to enhance its gross profit margin to 63.0%, up from 62.1% last year. This improvement is attributed to production efficiencies and a favourable product mix. Operating expenses remained well controlled despite inflationary pressures, especially in employment costs, underscoring effective cost management during a challenging economic environment.
Profit Outlook and Capital Project Progress
The company expects its net profit after tax to be between $10.0 million and $10.4 million, slightly below last year’s $10.4 million but within a stable range. Meanwhile, SDI’s Montrose project, a significant capital investment aimed at expanding production capabilities, is advancing steadily. Construction tenders have been received with bids ranging from $24 million to $25 million, and the preferred tender is expected to be selected by mid-July.
Planning permit approvals are progressing well, with construction anticipated to start in September 2025. The Board has confirmed that funding for the Montrose project will come from a combination of sale and leaseback of the existing Bayswater premises alongside debt financing, reflecting a strategic approach to capital management.
Looking Ahead
SDI’s full-year audited results will be released on August 28, 2025, accompanied by an investor conference call. These results will provide a clearer picture of the company’s financial health and the impact of its strategic initiatives, including the Montrose project’s progress and regional sales dynamics.
Bottom Line?
SDI’s steady financial footing and strategic capital moves set the stage for a pivotal year ahead.
Questions in the middle?
- How will the decline in Amalgam sales affect SDI’s long-term product strategy?
- What impact will the Montrose project have on production capacity and profitability?
- Can SDI sustain growth in Europe and Brazil amid challenges in other regions?